Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

Table 1

An overview of the research studies on ctDNA/ctDNA in ovarian cancer is summarized.

Author	Year	Application	Sample	Method	Target
Shao et al. [31]	2015	Diagnosis	Serum	bDNA technique	The levels of cfDNA
Kamat et al. [32]	2006	Diagnosis	Plasma	Real-time PCR	The levels of cfDNA
Capizzi et al. [33]	2008	Diagnosis/therapy response	Plasma	Real-time PCR	The levels of cfDNA
Pereira et al. [34]	2015	Diagnosis	Serum	Droplet digital PCR	The levels of ctDNA
Zhou et al. [35]	2016	Diagnosis	Peripheral blood	Quantitative real-time PCR	The levels and integrity of cfDNA
Stamenkovic et al. [36]	2020	Diagnosis	Peripheral blood	Quantitative real-time PCR	The levels and integrity of cfDNA
Yu et al. [37]	2019	Diagnosis	Peripheral blood	Quantitative real-time PCR	The levels and integrity of cfDNA
Otsukaet al. [38]	2004	Diagnosis	Plasma	F-SSCP	TP53 mutations
Park et al. [39]	2018	Diagnosis	Plasma	Digital PCR	TP53 mutations
Swisher et al. [40]	2005	Diagnosis	Peripheral blood	Ligase detection reaction	TP53 mutations
Battagli et al. [41]	2004	Diagnosis	Peripheral blood	MSP	BRCA1 and RASSF1A methylation
Dvorská et al. [42]	2019	Diagnosis	Plasma	MSP	Gene methylation
Wu et al. [43]	2014	Diagnosis	Serum	MSP	RASSFA methylation
Sandeep et al. [44]	2019	Diagnosis	Plasma	MSP	RASS1A and BRCA1 methylation
Li et al. [45]	2019	Diagnosis	Peripheral blood	NGS	Qualitative detection (methylation)
Wang et al. [46]	2017	Diagnosis	Serum	MSP	OPCML methylation
Liggett et al. [47]	2011	Diagnosis	Serum	NGS	DNA methylation
Widschwendter et al. [48]	2017	Diagnosis	Serum	Bisulfite sequencing	DNA methylation
Vanderstichele [49]	2017	Diagnosis	Plasma	Low-coverage whole-genome sequencing	Chromosomal instability
Cheng et al. [50]	2009	Therapy response	Plasma	Quantitative PCR	The levels of cfDNA
Kamat et al. [51]	2006	Therapy response	Plasma	Real-time PCR	The levels of cfDNA
Hufnagl et al. [52]	2020	Therapy response	Plasma	Quantitative RT-PCR	The levels of cfDNA
Arend et al. [53]	2018	Therapy response	Plasma	NGS	Mutations
Vitale et al. [54]	2020	Therapy response	Serum	NGS	TP53 mutations
Kim et al. [55]	2019	Therapy response	Plasma	Digital PCR	TP53 mutations
Parkinson et al. [56]	2016	Therapy response	Plasma	Microfluidic digital PCR	TP53 mutations
Harris et al. [57]	2016	Therapy response	Plasma	Quantitative PCR	Chromosomal rearrangements
Morikawa et al. [58]	2018	Therapy response	Plasma	Droplet digital PCR	PIK3CA and KRAS mutations
Christie et al. [59]	2017	Therapy response	Plasma	NGS	BRCA1/2 germline mutations
Steffensen et al. [60]	2014	Therapy response/prognosis	Plasma	Real-time PCR	The levels of cfDNA
Ratajska et al. [61]	2017	Therapy response	Plasma	NGS	BRCA1/2 mutations
Weigelt et al. [62]	2017	Therapy response	Plasma	NGS	BRCA1 and BRCA2 reversion mutations
Kamat et al. [63]	2010	Prognosis	Plasma	Real-time PCR	The levels of cfDNA
No et al. [64]	2012	Prognosis	Serum	Quantitative real-time PCR	The levels of cfDNA
Phallen et al. [65]	2017	Prognosis	Plasma	TES-seq	Genomic mutations
Dobrzyckaet al. [66]	2011	Prognosis	Plasma	PCR-RFLP	KRAS and TP53 mutations
Zhuang et al. [67]	2017	Prognosis	Peripheral blood	Meta-analysis	KRAS mutation
Giannopoulou et al. [68]	2018	Prognosis	Plasma	Real-time MSP	ESR1 methylation
Giannopoulou et al. [69]	2017	Prognosis	Plasma	Real-time MSP	RASSF1A methylation